This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardiovascular Systems (CSII) Q1 Earnings Top, Revenues Lag
by Zacks Equity Research
Cardiovascular Systems' (CSII) Q1 revenues declined year over year owing to the decline in revenues at both the segments.
Will Hurricanes Choke Cardiovascular (CSII) Q1 Performance?
by Zacks Equity Research
Cardiovascular (CSII) expects Q1 revenues to be affected by the Harvey and Irma hurricanes. However, the long-term growth prospects are unlikely to be affected.
Cardiovascular Systems (CSII) Down 3.5% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems (CSII) Catches Eye: Stock Jumps 6.9%
by Zacks Equity Research
Cardiovascular Systems (CSII) saw a big move last session, as its shares jumped nearly 7% on the day amid huge volumes.
Cardiovascular Systems Unveils Favorable LIBERTY 360 Data
by Zacks Equity Research
LIBERTY 360 Study shows the importance of endovascular intervention in patients with Critical Limb Ischemia (CLI) to prevent amputation.
Cardiovascular Systems Rides on Innovation Amid Several Woes
by Zacks Equity Research
Cardiovascular Systems' (CSII) low operating expenses and strong revenue performance contributed to the upside in Q2 earnings.
Cardiovascular Systems (CSII) Posts Q4 Earnings, Revenues Top
by Zacks Equity Research
Cardiovascular Systems' (CSII) lower operating expenses drove the year-over-year improvement in Q4 earnings.
Cardiovascular Systems (CSII) in Focus: Stock Moves 8.4% Higher
by Zacks Equity Research
Cardiovascular Systems, Inc. (CSII) was a big mover last session, as the company saw its shares rise over 8% on the day.
Cardiovascular Systems (CSII) Hits 52-Week High on Solid Q3
by Zacks Equity Research
Share price of Cardiovascular Systems, Inc. (CSII) scaled a new 52-week high of $32.68 on Jun 9, eventually closing a bit lower at $30.93.
Cardiovascular Systems Innovation On Track, Competition Rife
by Zacks Equity Research
On Jun 6, we issued an updated research report on St. Paul, MN-based Cardiovascular Systems, Inc. (CSII).
Cardiovascular Systems (CSII) Up 2.3% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardiovascular Systems (CSII) Swings to Earnings in Q3
by Zacks Equity Research
Cardiovascular Systems, Inc. (CSII) reported adjusted earnings per share of 3 cents in third-quarter fiscal 2017, reflecting a massive improvement from the year-ago quarter's adjusted loss of 47 cents.
Zacks.com featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and Infrastructure, Genomic Health and Par Pacific Holdings
by Zacks Equity Research
Zacks.com featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and Infrastructure, Genomic Health and Par Pacific Holdings
A Company's First Profit Can Mean Big Profits to Investors
by Kevin Matras
Kevin Matras screens for companies showing their 'first profit' and explains why they are ones to watch. Highlighted stocks include COG, CSII, FTAI, GHDX and PARR.
STERIS Continues to Trade Below Industry on Dull Outlook
by Zacks Equity Research
On Mar 16, we issued an updated research report on Ohio-based STERIS plc (STE).
Integra (IART) Titan Reverse Launch Expands Extremity Line
by Zacks Equity Research
Integra LifeSciences (IART) recently broadened its extremity product line with the launch of its Titan Press-Fit Reverse Shoulder for Fracture.
Medtronic's New Reveal LINQ ICM Gets FDA 510(k) Clearance
by Zacks Equity Research
Medical device major, Medtronic plc (MDT) recently received the U.S. FDA 510(k) clearance for its Reveal LINQ Insertable Cardiac Monitor (ICM) with TruRhythm Detection.
IDEXX (IDXX) Poised on Strong Fundamentals, Innovations
by Zacks Equity Research
On Mar 14, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
Medtronic's Pacemaker Business Wins CMS Coverage Approval
by Zacks Equity Research
Medtronic plc (MDT) recently won the U.S. CMS coverage approval for its Micra Transcatheter Pacing System (TPS).
Myriad Genetics (MYGN) Launches EndoPredict Test in the US
by Zacks Equity Research
Myriad Genetics, Inc. (MYGN), a leading name in the molecular diagnostics space, recently launched the EndoPredict test in the U.S. for patients with ER+ HER2 -- early-stage breast cancer.
The Zacks Analyst Blog Highlights: Inogen, OraSure Technologies, Lannett and Cardiovascular Systems
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Inogen, OraSure Technologies, Lannett and Cardiovascular Systems
Amedisys Stock Up on Solid Earnings, Reimbursement Woes Stay
by Zacks Equity Research
On Mar 02, we issued an updated research report on renowned home health and hospice services provider Amedisys Inc. (AMED).
VWR Corp Poised on Strong Earnings Amid Currency Headwinds
by Zacks Equity Research
On Feb 28, we issued an updated research report on VWR Corporation (VWR), an independent worldwide provider of products, services and solutions to laboratory and production facilities.
Baxter Partners ScinoPharm, Expands in Generic Injectables
by Zacks Equity Research
Baxter International Inc. (BAX) has formed a strategic partnership with Taiwan-based process R&D and active pharmaceutical ingredient (API) manufacturer, ScinoPharm Taiwan, Ltd.
Hill-Rom Holdings Hits a 52-Week High on Solid Prospects
by Zacks Equity Research
Share price of Batesville, IN-based Hill-Rom Holdings, Inc.(HRC) scaled a new 52-week high of $67.44 on Mar 1, eventually closing a tad lower at $67.21.